Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Charu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH Physician

Leslye M. Heisler Assistant Professor for Lung Cancer Excellence

Dr. Aggarwal is employed by Penn Medicine.

About Dr. Charu Aggarwal

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches including cellular therapy and CAR-T for solid tumors.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2011
  • Medical Oncology, 2011

Clinical Expertise:

  • Head and Neck Cancer
  • Lung Cancer

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Lady Hardinge Medical College
Residency: SUNY at Buffalo Medical Center
Fellowship: Fox Chase Cancer Center

Memberships

American Association of Cancer Research, National American Society of Clinical Oncology, National Eastern Cooperative Oncology Group, National International Association for the Study of Lung Cancer, International National Cancer Institute (NCI), National

Hospital Affiliation

Dr. Aggarwal is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Dr. Aggarwal is the Leslye Heisler Assistant Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principle investigator for multiple clinical trials focusing on the development of “targeted” immunotherapeutic approaches including cellular therapy and CAR-T for solid tumors. Dr. Aggarwal has led the development of a DNA plasmid based HPV specific immunotherapy for HPV associated head and neck cancers. She is actively involved in evaluating the role of plasma-based NGS in management of patients with metastatic lung cancer.

She has extensive experience in the planning, design and execution of clinical trials, is an active member of ECOG, and has served as a national sub-study chair for SWOG-NCI’s LUNG-MAP. She has served on the Annual Meeting Scientific Program Committee of American Society of Clinical Oncology (ASCO), ASCO Education Committee, NCI- Head and Neck Metastatic Task Force Steering Committee and ACC’s Data Safety and Monitoring Committee. Dr. Aggarwal’s ultimate goal as a clinical and translational investigator is to perform patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung and Head and Neck Cancer.

Selected Publications:

Beck TN, Boumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, Vlasenkova R, Rao C, Borghaei H, Cristofanilli M, Mehra R, Serebriiskii I, Alpaugh RK.: Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC Cancer 19(1):603 : doi: 10.1186/s12885-019-5795-x,2019.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.: Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. : doi: 10.1200/JCO.19.00934. [Epub ahead of print],2019.

Balata H, Fong KM, Hendriks LE, Lam S, Ostroff JS, Peled N, Wu N, Aggarwal C: Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 J Thorac Oncol : doi: 10.1016/j.jtho.2019.06.011,2019.

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA: Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. : doi: 10.1016/j.jtho.2019.05.029. [Epub ahead of print],2019.

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.: Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. : doi: 10.1200/JCO.19.00934.,2019.

Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB: Pembrolizumab in patients with advanced non-small-cell lung cancer(KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respiratory Medicine : pii: S2213-2600(18)30500-9,2019.

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL: Hepatocytes direct the formation of a pro-metastatic niche in the liver Nature. 2019 Mar 6. doi: 10.1038/s41586-019-1004-y. [Epub ahead of print] : 2019.

Swed BL, Cohen RB, Aggarwal C: Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience JCO Precision Oncology 3 : doi: 10.1200/PO.18.00351. Epub 2019 Feb 15,2019.

Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS: Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. Journal of Clinical Oncology. 2018. Dec 5:JCO1800264. doi: 10.1200/JCO.18.00264. [Epub ahead of print] : 2018.

Aggarwal C, Albelda SM: Molecular Characterization of Malignant Mesothelioma: Time for New Targets? Cancer Discovery 8 (12): 1508-1510,2018.

Academic Contact Info

Perelman Center for Advanced Medicine
10-137, South Pavilion
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 662-6318
Patient appointments: 800-789-7366 (PENN)